Lipocine (NASDAQ: LPCN) seeks clarity on LPCN 2401 study
Rhea-AI Filing Summary
Lipocine Inc. reported that it has updated the corporate presentation it uses with investors, analysts and other audiences. The update reflects the current status of LPCN 2401, a program being developed as an adjunct to GLP-1 therapy.
The company has received IND clearance to proceed with a proof-of-concept study of LPCN 2401, but is first seeking regulatory clarity on the development path, including study endpoints such as functional loss, before moving forward with the study. The revised investor presentation has been filed as Exhibit 99.1 to this report.
Positive
- None.
Negative
- None.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported):
(Exact name of registrant as specified in its charter)
Commission
File No.
(State or other jurisdiction of incorporation) |
(IRS Employer Identification Number) |
(Address of principal executive offices) (Zip Code)
Registrant’s
telephone number, including area code:
Former name or former address, if changed since last report: Not Applicable
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR § 230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR § 240.12b-2).
Emerging
growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
| Item 8.01 | Other Events |
The Company has updated its corporate presentation that it uses when meeting with investors, analysts and others. Although the Company has received IND clearance to proceed with the POC study of LPCN 2401 as an adjunct to GLP-1 therapy, the Company is seeking regulatory clarity regarding the development path for LPCN 2401, in particular study endpoints such as functional loss, before proceeding with the POC study. The corporate presentation has been updated accordingly. The presentation is filed as Exhibit 99.1.
| Item 9.01 | Financial Statements and Exhibits. |
| (d) | Exhibits |
The following exhibits are filed with this report:
| Exhibit No. | Description | |
| 99.1 | Corporate Presentation | |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| LIPOCINE INC. | ||||
| Date: | September 26, 2025 | By: | /s/ Mahesh V. Patel | |
| Mahesh V. Patel | ||||
| President and Chief Executive Officer | ||||
FAQ
What did Lipocine (LPCN) disclose in this 8-K filing?
What is the current status of Lipocine’s LPCN 2401 program?
Why is Lipocine seeking regulatory clarity before the LPCN 2401 POC study?
How does LPCN 2401 relate to GLP-1 therapy?
Where can investors find Lipocine’s updated corporate presentation?
Does this Lipocine 8-K involve any major transactions or financings?
